Dr. Reddy’s Laboratories Ltd (NYSE:RDY) – Research analysts at Jefferies Group dropped their FY2018 earnings estimates for shares of Dr. Reddy’s Laboratories in a research note issued to investors on Tuesday. Jefferies Group analyst P. Nahar now forecasts that the company will earn $1.14 per share for the year, down from their previous estimate of $1.28. Jefferies Group has a “Underperform” rating and a $30.51 price target on the stock. Jefferies Group also issued estimates for Dr. Reddy’s Laboratories’ FY2019 earnings at $1.88 EPS and FY2020 earnings at $2.21 EPS.

TRADEMARK VIOLATION WARNING: “Jefferies Group Weighs in on Dr. Reddy’s Laboratories Ltd’s FY2018 Earnings (RDY)” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/11/02/jefferies-group-weighs-in-on-dr-reddys-laboratories-ltds-fy2018-earnings-rdy.html.

A number of other equities analysts have also commented on RDY. Zacks Investment Research upgraded Dr. Reddy’s Laboratories from a “strong sell” rating to a “hold” rating in a research note on Tuesday, September 26th. BidaskClub lowered Dr. Reddy’s Laboratories from a “hold” rating to a “sell” rating in a research note on Monday, July 31st. Morgan Stanley upgraded Dr. Reddy’s Laboratories from an “equal weight” rating to an “overweight” rating in a research note on Thursday, September 21st. Finally, CLSA lowered Dr. Reddy’s Laboratories from an “underperform” rating to a “sell” rating in a research note on Friday, July 28th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company. Dr. Reddy’s Laboratories presently has an average rating of “Hold” and a consensus target price of $30.51.

Large investors have recently bought and sold shares of the business. SG Americas Securities LLC acquired a new position in Dr. Reddy’s Laboratories during the 2nd quarter worth $144,000. Airain ltd acquired a new position in Dr. Reddy’s Laboratories during the 2nd quarter worth $223,000. DekaBank Deutsche Girozentrale acquired a new position in Dr. Reddy’s Laboratories during the 2nd quarter worth $237,000. Dynamic Technology Lab Private Ltd acquired a new position in Dr. Reddy’s Laboratories during the 2nd quarter worth $286,000. Finally, Bank of New York Mellon Corp acquired a new position in Dr. Reddy’s Laboratories during the 1st quarter worth $297,000. 15.23% of the stock is currently owned by hedge funds and other institutional investors.

Dr. Reddy’s Laboratories Company Profile

Dr. Reddy’s Laboratories Limited is a pharmaceutical company that is engaged in providing medicines. The Company operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment includes manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics).

Earnings History and Estimates for Dr. Reddy`s Laboratories (NYSE:RDY)

Receive News & Ratings for Dr. Reddy's Laboratories Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dr. Reddy's Laboratories Ltd and related companies with MarketBeat.com's FREE daily email newsletter.